MX2023000947A - Peptidos grapados y metodos para su obtencion. - Google Patents
Peptidos grapados y metodos para su obtencion.Info
- Publication number
- MX2023000947A MX2023000947A MX2023000947A MX2023000947A MX2023000947A MX 2023000947 A MX2023000947 A MX 2023000947A MX 2023000947 A MX2023000947 A MX 2023000947A MX 2023000947 A MX2023000947 A MX 2023000947A MX 2023000947 A MX2023000947 A MX 2023000947A
- Authority
- MX
- Mexico
- Prior art keywords
- present disclosure
- disclosure provides
- catenin
- beta
- agents
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000015735 Beta-catenin Human genes 0.000 abstract 3
- 108060000903 Beta-catenin Proteins 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000005516 engineering process Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Entre otras cosas, la presente divulgación proporciona diversos agentes. En algunas modalidades, los agentes proporcionados pueden unirse a la beta-catenina. En algunas modalidades, la presente divulgación proporciona tecnologías para modular las funciones de beta-catenina. En algunas modalidades, la presente divulgación proporciona tecnologías para prevenir y/o tratar afecciones, trastornos o enfermedades asociadas con beta-catenina. En algunas modalidades, la presente divulgación proporciona aminoácidos diseñados que pueden proporcionar propiedades y/o actividades mejoradas. En algunas modalidades, la presente divulgación proporciona agentes que comprenden dichos aminoácidos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055308P | 2020-07-22 | 2020-07-22 | |
| US202163208494P | 2021-06-08 | 2021-06-08 | |
| PCT/US2021/042856 WO2022020652A2 (en) | 2020-07-22 | 2021-07-22 | Stapled peptides and methods thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000947A true MX2023000947A (es) | 2023-02-22 |
Family
ID=79728982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000947A MX2023000947A (es) | 2020-07-22 | 2021-07-22 | Peptidos grapados y metodos para su obtencion. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240116985A1 (es) |
| EP (1) | EP4185599A2 (es) |
| JP (1) | JP2023535026A (es) |
| KR (1) | KR20230057350A (es) |
| CN (1) | CN116323638A (es) |
| AU (1) | AU2021314310A1 (es) |
| CA (1) | CA3186681A1 (es) |
| IL (1) | IL299907A (es) |
| MX (1) | MX2023000947A (es) |
| WO (1) | WO2022020652A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202090513A1 (ru) | 2017-09-07 | 2020-08-24 | Фог Фармасьютикалз, Инк. | Агенты, модулирующие функции бета-катенина, и связанные способы |
| CN115260060A (zh) * | 2022-09-07 | 2022-11-01 | 康化（上海）新药研发有限公司 | (2s)-2-n-芴甲氧羰基氨基-5,5-二甲基正亮氨酸的合成方法 |
| WO2024054892A1 (en) * | 2022-09-09 | 2024-03-14 | Shape Therapeutics Inc. | Therapeutic peptides |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040181830A1 (en) * | 2001-05-07 | 2004-09-16 | Kovalic David K. | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| EA202090513A1 (ru) * | 2017-09-07 | 2020-08-24 | Фог Фармасьютикалз, Инк. | Агенты, модулирующие функции бета-катенина, и связанные способы |
| US20200408746A1 (en) * | 2018-03-14 | 2020-12-31 | Dana-Farber Cancer Institute, Inc. | Stabilized Peptides for Biomarker Detection |
-
2021
- 2021-07-22 MX MX2023000947A patent/MX2023000947A/es unknown
- 2021-07-22 AU AU2021314310A patent/AU2021314310A1/en active Pending
- 2021-07-22 IL IL299907A patent/IL299907A/en unknown
- 2021-07-22 CA CA3186681A patent/CA3186681A1/en active Pending
- 2021-07-22 EP EP21847152.2A patent/EP4185599A2/en active Pending
- 2021-07-22 US US18/017,024 patent/US20240116985A1/en active Pending
- 2021-07-22 CN CN202180064601.7A patent/CN116323638A/zh active Pending
- 2021-07-22 WO PCT/US2021/042856 patent/WO2022020652A2/en unknown
- 2021-07-22 JP JP2023504288A patent/JP2023535026A/ja active Pending
- 2021-07-22 KR KR1020237005577A patent/KR20230057350A/ko unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023535026A (ja) | 2023-08-15 |
| US20240116985A1 (en) | 2024-04-11 |
| IL299907A (en) | 2023-03-01 |
| WO2022020652A2 (en) | 2022-01-27 |
| WO2022020652A3 (en) | 2022-03-03 |
| CA3186681A1 (en) | 2022-01-27 |
| CN116323638A (zh) | 2023-06-23 |
| AU2021314310A1 (en) | 2023-03-16 |
| EP4185599A2 (en) | 2023-05-31 |
| KR20230057350A (ko) | 2023-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000947A (es) | Peptidos grapados y metodos para su obtencion. | |
| CR20220178A (es) | Compuestos moduladores de glp-1r | |
| MX2022009947A (es) | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos. | |
| PH12018500233A1 (en) | Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof | |
| MX2022003718A (es) | Anticuerpos que se unen a cd39 y sus usos. | |
| MX2020002435A (es) | Agentes que modulan las funciones de beta-catenina y sus métodos. | |
| MX2018009498A (es) | Anticuerpos anti-tnf, composiciones, métodos y uso para el tratamiento o la prevención de la diabetes tipo 1. | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| EA200901067A1 (ru) | Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов | |
| EA201100072A1 (ru) | Новые композиции и способы | |
| EA202190708A1 (ru) | Модуляторы экспрессии pnpla3 | |
| MX2022008659A (es) | Moléculas de anticuerpos específicos contra c5ar1 y usos de estas. | |
| MX2019008989A (es) | Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa. | |
| EP4269562A3 (en) | Antigen binding molecules and methods of use thereof | |
| SG11202000115SA (en) | Novel therapeutic enzyme fusion protein and use thereof | |
| AU2021269176A8 (en) | Single domain antibodies binding to SARS-CoV-2 spike protein | |
| MX2022011077A (es) | Variantes de transglutaminasa. | |
| WO2019094533A8 (en) | Angptl8-binding agents and methods of use thereof | |
| BR112023025528A2 (pt) | Peptídeos grampeados e métodos destes | |
| MX2010001187A (es) | Moduladores del receptor ccr9 y metodos para su uso. | |
| MX2022000081A (es) | Proteínas de unión al antígeno anti carcinoma de células escamosas esofágico 1 de nueva york (ny-eso-1) y métodos de uso. | |
| MX2018004164A (es) | Inhibidores de sumoilacion de crmp2 y usos de los mismos. | |
| MX2021004976A (es) | Anticuerpo fn14 antihumano. | |
| WO2022271814A3 (en) | Short apoc-ii mimetic peptides and methods of use | |
| WO2017096431A8 (en) | Proteinaceous molecules and methods of use |